UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tracking implementation strategies in the randomized rollout of a Veterans Affairs national opioid risk management initiative

Implementation science : IS, 2020-06, Vol.15 (1), p.48-48, Article 48

2020

Volltextzugriff (PDF)

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

Journal of clinical oncology, 2021-07, Vol.39 (20), p.JCO2003488-2303

2021

Volltextzugriff (PDF)

Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer

Prostate cancer, 2022-09, Vol.2022, p.5454727-12

2022

Volltextzugriff (PDF)

Tracking the randomized rollout of a Veterans Affairs opioid risk management tool: A multi-method implementation evaluation using the Consolidated Framework for Implementation Research (CFIR)

Implementation research and practice, 2022-01, Vol.3, p.26334895221114665-26334895221114665

2022

Volltextzugriff (PDF)

Radiographic progression-free survival in the ACIS trial for prostate cancer – Authors' reply

The lancet oncology, 2022-01, Vol.23 (1), p.e5-e6

2022

Volltextzugriff (PDF)

Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study

European journal of cancer (1990), 2023-11, Vol.193, p.113290, Article 113290

2023

Volltextzugriff (PDF)

Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN

British journal of cancer, 2024-01, Vol.130 (1), p.73-81

2024

Volltextzugriff (PDF)

Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies

Future oncology (London, England), 2024-08, p.1

2024

Volltextzugriff (PDF)

Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study

Future oncology (London, England), 2024-03, Vol.20 (10), p.563-578

2024

Volltextzugriff (PDF)

Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer

European urology oncology, 2024-08, Vol.7 (4), p.844-852

2024

Volltextzugriff (PDF)

Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature Review

European urology oncology, 2024-05

2024

Volltextzugriff (PDF)

Comparing Colorectal Cancer Screening Outcomes in the International Cancer Screening Network: A Consortium Proposal

Gastroenterology (New York, N.Y. 1943), 2022-03, Vol.162 (3), p.668-674

2022

Volltextzugriff (PDF)

Effects of Clopidogrel Added to Aspirin in Patients with Recent Lacunar Stroke

The New England journal of medicine, 2012-08, Vol.367 (9), p.817-825

2012

Volltextzugriff (PDF)

Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial

Lancet neurology, 2014-12, Vol.13 (12), p.1177-1185

2014

Volltextzugriff (PDF)

C-Reactive Protein as a Prognostic Marker After Lacunar Stroke: Levels of Inflammatory Markers in the Treatment of Stroke Study

Stroke (1970), 2014-03, Vol.45 (3), p.707-716

2014

Volltextzugriff (PDF)

MP60-02 REAL WORLD TREATMENT SEQUENCE AND SURVIVAL IN LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER AND POSTPROGRESSION DISEASE STATES

The Journal of urology, 2024-05, Vol.211 (5S)

2024

Volltextzugriff (PDF)

Innovative interventions for today's exceptional children: Cultivating a passion for compassion

2009

Volltextzugriff (PDF)

PD34-11 PROSTATE-SPECIFIC ANTIGEN KINETICS IN PATIENTS WITH ADVANCED PROSTATE CANCER TREATED WITH APALUTAMIDE: RESULTS FROM THE TITAN AND SPARTAN STUDIES

The Journal of urology, 2021-09, Vol.206 (Supplement 3)

2021

Volltextzugriff (PDF)

Abstract 359: Molecular signatures associated with long-term response to apalutamide (APA) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in TITAN

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.359-359

2021

Volltextzugriff (PDF)

Apalutamide plus abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, phase 3 study

The lancet oncology, 2021-09, Vol.22 (11), p.1541-1559

2021

Volltextzugriff (PDF)

MP24-08 RELATIONSHIPS OF SITES AND BURDEN OF METASTASES WITH LONG-TERM OUTCOMES AND MOLECULAR SUBTYPES IN TITAN

The Journal of urology, 2021-09, Vol.206 (Supplement 3)

2021

Volltextzugriff (PDF)

Long range effects of the aluminum avoidance principle

Analytical chemistry (Washington), 1985-11, Vol.57 (13), p.2733-2735

1985

Volltextzugriff (PDF)

Alkene transformations catalysed by mineral matter during oil shale pyrolysis

Organic geochemistry, 1986, Vol.9 (5), p.245-253

1986

Volltextzugriff (PDF)

1 – 25 von 352

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(298)
Mit Volltextzugriff
(273)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(351)
Norwegisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Tracking implementation strategies in the randomized rollout of a Veterans Affairs national opioid risk management initiative

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer

Tracking the randomized rollout of a Veterans Affairs opioid risk management tool: A multi-method implementation evaluation using the Consolidated Framework for Implementation Research (CFIR)

Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study

Radiographic progression-free survival in the ACIS trial for prostate cancer – Authors' reply

Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy

Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study

Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN

Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies

Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study

Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer

Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature Review

Comparing Colorectal Cancer Screening Outcomes in the International Cancer Screening Network: A Consortium Proposal

Effects of Clopidogrel Added to Aspirin in Patients with Recent Lacunar Stroke

Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial

C-Reactive Protein as a Prognostic Marker After Lacunar Stroke: Levels of Inflammatory Markers in the Treatment of Stroke Study

MP60-02 REAL WORLD TREATMENT SEQUENCE AND SURVIVAL IN LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER AND POSTPROGRESSION DISEASE STATES

Innovative interventions for today's exceptional children: Cultivating a passion for compassion

PD34-11 PROSTATE-SPECIFIC ANTIGEN KINETICS IN PATIENTS WITH ADVANCED PROSTATE CANCER TREATED WITH APALUTAMIDE: RESULTS FROM THE TITAN AND SPARTAN STUDIES

Abstract 359: Molecular signatures associated with long-term response to apalutamide (APA) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in TITAN

Apalutamide plus abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, phase 3 study

MP24-08 RELATIONSHIPS OF SITES AND BURDEN OF METASTASES WITH LONG-TERM OUTCOMES AND MOLECULAR SUBTYPES IN TITAN

Long range effects of the aluminum avoidance principle

Alkene transformations catalysed by mineral matter during oil shale pyrolysis

Suchergebnisse filtern